Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer.

Ishizaki F, Hara N, Takizawa I, Nishiyama T, Isahaya E, Kawasaki T, Takahashi K.

Growth Horm IGF Res. 2012 Jun-Aug;22(3-4):122-8. doi: 10.1016/j.ghir.2012.04.003. Epub 2012 May 11.

PMID:
22579549
2.

Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.

Hara N, Takizawa I, Isahaya E, Nishiyama T, Hoshii T, Ishizaki F, Takahashi K.

Urol Oncol. 2012 Sep;30(5):596-601. doi: 10.1016/j.urolonc.2010.11.001. Epub 2011 Apr 1.

PMID:
21458314
3.

Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.

Isahaya E, Hara N, Nishiyama T, Hoshii T, Takizawa I, Takahashi K.

Prostate. 2010 Feb 1;70(2):155-61. doi: 10.1002/pros.21047.

PMID:
19760629
4.

Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis.

Hara N, Nishiyama T, Takizawa I, Saito T, Kitamura Y, Takahashi K.

Urology. 2010 Jun;75(6):1441-5. doi: 10.1016/j.urology.2009.11.021. Epub 2010 Jan 29.

PMID:
20110105
5.

Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers.

Hara N, Ishizaki F, Saito T, Nishiyama T, Kawasaki T, Takahashi K.

Urology. 2013 Feb;81(2):376-80. doi: 10.1016/j.urology.2012.10.050.

PMID:
23374809
6.

Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy.

Komatsu S, Hara N, Ishizaki F, Nishiyama T, Takizawa I, Isahaya E, Kawasaki T, Takahashi K.

Prostate. 2012 Aug 1;72(11):1207-13. doi: 10.1002/pros.22471. Epub 2011 Dec 27.

PMID:
22213519
7.

Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.

Takizawa I, Nishiyama T, Hara N, Isahaya E, Hoshii T, Takahashi K.

Prostate. 2010 Sep 15;70(13):1395-401. doi: 10.1002/pros.21174.

PMID:
20687212
8.

Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.

Takizawa I, Hara N, Nishiyama T, Isahaya E, Hoshii T, Takahashi K.

J Urol. 2010 Nov;184(5):1971-6. doi: 10.1016/j.juro.2010.06.115.

PMID:
20884032
10.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

Prostate Cancer Prostatic Dis. 2002;5(4):304-10.

11.
12.

Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy.

Kim SO, Kang TW, Kwon D, Park K, Ryu SB.

Int Braz J Urol. 2009 Mar-Apr;35(2):183-8; discussion 189.

13.

Long-term effects of androgen deprivation therapy in prostate cancer patients.

Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.

Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86.

PMID:
12072048
14.

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

Kiratli BJ, Srinivas S, Perkash I, Terris MK.

Urology. 2001 Jan;57(1):127-32.

PMID:
11164157
15.

Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids.

García-Fontana B, Morales-Santana S, Varsavsky M, García-Martín A, García-Salcedo JA, Reyes-García R, Muñoz-Torres M.

Osteoporos Int. 2014 Feb;25(2):645-51. doi: 10.1007/s00198-013-2462-y. Epub 2013 Aug 1.

PMID:
23903956
16.

Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia.

Guo CY, Weetman AP, Eastell R.

Clin Endocrinol (Oxf). 1996 Nov;45(5):535-41.

PMID:
8977749
17.

Effects of DHEA replacement on bone mineral density and body composition in elderly women and men.

Villareal DT, Holloszy JO, Kohrt WM.

Clin Endocrinol (Oxf). 2000 Nov;53(5):561-8.

PMID:
11106916
18.

Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.

Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miwa S, Maeda Y, Kadono Y, Takashima M, Koh E, Namiki M.

Urology. 2009 Jun;73(6):1342-6. doi: 10.1016/j.urology.2009.01.046. Epub 2009 Apr 15.

PMID:
19371939
19.

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

Morabito N, Gaudio A, Lasco A, Catalano A, Atteritano M, Trifiletti A, Anastasi G, Melloni D, Frisina N.

J Bone Miner Res. 2004 Nov;19(11):1766-70. Epub 2004 Aug 23.

20.

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.

Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM.

J Clin Endocrinol Metab. 2005 Dec;90(12):6410-7. Epub 2005 Sep 27.

PMID:
16189261

Supplemental Content

Support Center